The European Medicines Agency (EMA) and the pharmaceutical industry look to be set on a collision course regarding the vexed issue of access to clinical trial data, following the joint publication of a set of principles on the topic by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA).